Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arimidex and Nolvadex PK in postmenopausal breast cancer
NCT00784862Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 1998
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of anastrozole in breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoints: Steady state plasma trough concentration of anastrozole at 24 hours, Steady state plasma trough concentration of tamoxifen at 24 hours and 1 more. Started Jun 1998; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00784862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784862.